OPXA in discussions on partnership for its MS DRUG
Based on what XOMA just recently got on a partnership, I see OPXA getting a similar type deal because the MS Drug has such a large market in the multi-billions on yearly sales with only a handful of companies splitting the sales.
CEO of OPXA wrote in a letter to shareholders: We remain engaged in discussions with potential industry partners concerning the Tovaxin opportunity.
XOMA XOMA Limited target raised to $16 at Ladenburg Thalmann following partnership for XOMA-052 (6.67 )
Ladenburg Thalmann raises their XOMA tgt to $16 from $12. Servier's Development and Commercialization Agreement with XOMA for XOMA-052 consists of $35 mln in upfront cash and approx €355 ($470) mln in future development and commercial milestones for multiple indications and tiered royalties (from mid-single digit to mid-teens) on sales. Development of XOMA-052 for cardiovascular and diabetes indications are fully funded by Servier. Of note, although Servier will have worldwide rights to XOMA-052 for diabetes and cardiovascular indications, XOMA has the option to reacquire U.S. and Japanese rights to XOMA-052 for these indications.